tradingkey.logo

tradingkey.logo
怜玢


United Therapeutics Corp

UTHR
りォッチリストに远加
598.720USD
+5.180+0.87%
終倀 10-30 16:00ET
25.68B時䟡総額
20.44盎近12ヶ月PER

United Therapeutics Corpに぀いお 䌁業名

United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.

United Therapeutics Corp プロフィヌル


䌁業コヌドUTHR
䌚瀟名United Therapeutics Corp
䞊堎日Jun 17, 1999
最高経営責任者「CEO」Rothblatt (Martine A)
埓業員数1305
蚌刞皮類Ordinary Share
決算期末Jun 17
本瀟所圚地1000 Spring St
郜垂SILVER SPRING
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜United States of America
郵䟿番号20910
電話番号13016089292
りェブサむトhttps://www.unither.com/
䌁業コヌドUTHR
䞊堎日Jun 17, 1999
最高経営責任者「CEO」Rothblatt (Martine A)

United Therapeutics Corpの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Dr. Martine A. Rothblatt, J.D., Ph.D.
Dr. Martine A. Rothblatt, J.D., Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
690.66K
--
Dr. Martine A. Rothblatt, J.D., Ph.D.
Dr. Martine A. Rothblatt, J.D., Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
690.66K
--
Mr. Paul A. Mahon, J.D.
Mr. Paul A. Mahon, J.D.
Executive Vice President, General Counsel, and Corporate Secretary
Executive Vice President, General Counsel, and Corporate Secretary
45.17K
--
Mr. Paul A. Mahon, J.D.
Mr. Paul A. Mahon, J.D.
Executive Vice President, General Counsel, and Corporate Secretary
Executive Vice President, General Counsel, and Corporate Secretary
45.17K
--
Mr. Richard A. Giltner
Mr. Richard A. Giltner
Independent Director
Independent Director
21.88K
+5.99%
Mr. Richard A. Giltner
Mr. Richard A. Giltner
Independent Director
Independent Director
21.88K
+5.99%
Mr. Michael Benkowitz
Mr. Michael Benkowitz
President and Chief Operating Officer
President and Chief Operating Officer
21.39K
+87.62%
Mr. Michael Benkowitz
Mr. Michael Benkowitz
President and Chief Operating Officer
President and Chief Operating Officer
21.39K
+87.62%
Prof. Nilda Mesa, J.D.
Prof. Nilda Mesa, J.D.
Independent Director
Independent Director
5.58K
-1.76%
Prof. Nilda Mesa, J.D.
Prof. Nilda Mesa, J.D.
Independent Director
Independent Director
5.58K
-1.76%
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Dr. Martine A. Rothblatt, J.D., Ph.D.
Dr. Martine A. Rothblatt, J.D., Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
690.66K
--
Dr. Martine A. Rothblatt, J.D., Ph.D.
Dr. Martine A. Rothblatt, J.D., Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
690.66K
--
Mr. Paul A. Mahon, J.D.
Mr. Paul A. Mahon, J.D.
Executive Vice President, General Counsel, and Corporate Secretary
Executive Vice President, General Counsel, and Corporate Secretary
45.17K
--
Mr. Paul A. Mahon, J.D.
Mr. Paul A. Mahon, J.D.
Executive Vice President, General Counsel, and Corporate Secretary
Executive Vice President, General Counsel, and Corporate Secretary
45.17K
--
Mr. Richard A. Giltner
Mr. Richard A. Giltner
Independent Director
Independent Director
21.88K
+5.99%
Mr. Richard A. Giltner
Mr. Richard A. Giltner
Independent Director
Independent Director
21.88K
+5.99%

よくある質問

United Therapeutics Corpの䞊䜍5名の株䞻は誰ですか


United Therapeutics Corpの䞊䜍5名の株䞻は以䞋のずおりです。Dr. Martine A. Rothblatt, J.D., Ph.D.

United Therapeutics CorpUTHRの株匏を保有しおいる機関の数はいく぀ですか


2026Q1時点で、United Therapeutics Corpの株匏を保有しおいる機関は1548瀟あり、保有株匏の総垂堎䟡倀は玄42.91Mで、党䜓の101.10%を占めおいたす。2025Q4ず比范しお、機関の持ち株は-1413631.00増加しおいたす。

United Therapeutics Corpの最倧の収益源は䜕ですか


2026Q1においお、Tyvaso DPI郚門がUnited Therapeutics Corpにずっお最倧の収益を生み出しおおり、その金額は326.60Mで、党収益の41.70%を占めおいたす。
tradingkey.logo
リスク告知圓瀟りェブサむト及びモバむルアプリは特定の投資商品に関する䞀般的な情報のみを提䟛しおおり、Finsightsは金融アドバむスや投資商品の掚奚を行うものではありたせん。本情報の提䟛をもっおFinsightsが投資助蚀を行っおいるず解釈されるこずはありたせん。
投資商品には元本割れを含む重倧なリスクが䌎い、党おの投資家に適するものではありたせん。なお、過去の運甚実瞟は将来の成果を保蚌するものではありたせん。
Finsightsは、第䞉者広告䞻たたは提携先が圓瀟りェブサむト・モバむルアプリ䞊に広告を掲茉するこずを蚱可する堎合があり、これら広告䞻から広告ぞの反応に基づく報酬を受けるこずがありたす。
© 著䜜暩: FINSIGHTS MEDIA PTE. LTD. 無断耇写・転茉を犁じたす。